ADMET and DMPK

Aims & Scope

ADMET and DMPK is an open-access journal devoted to the rapid dissemination of new and original scientific results in medicinal chemistry, natural product, biophysical chemistry, analytical science, advanced materials, pharmacology and pharmacy. Particular emphases of the Journal are placed on understanding of the interactions between therapeutic agents (either synthetic or naturally occurring) and biological systems, in the context of in vitro and/or in vivo systems, including absorption, distribution, metabolism, excretion, toxicology or pharmacokinetics. The therapeutic areas of interest of the Journal include, but are not limited to: oncology, neuroscience, infection, cardiovascular, respiratory and immunology. For manuscripts reporting novel synthetic compounds, the Journal requires that: (1) the characterization data (e.g. HRMS, NMR) of the compounds must be included, (2) the molecular target of the compounds described must be known, and (3) must be demonstrated experimentally. For studies involving natural products, if the molecular target is unknown, some data to provide insight into the mechanism of action is required. The Journal does accept submission on the actions of biological extracts of unknown chemical composition and//or unknown concentration. Studies supported by molecular docking and/or in silico predictions may be accepted provided that novel insights in molecular design and target engagement are revealed and must be supported by experimental data. Studies dealing with novel physiological based pharmacokinetic modeling approaches that complied with the Journal’s Modelling and simulation ethics ( https://pub.iapchem.org/ojs/index.php/admet/pbpk ) are particularly welcome. The Journal encourages studies dealing with latest progresses in materials science and their novel applications in the field of pharmacology and/or pharmacy. ADMET and DMPK welcome translational pharmacological studies including preclinical and early clinical proof-of-concept case studies. However, the Journal does not publish first in man phase I, phase II, III or IV studies. Studies based solely on meta-analysis are not acceptable.

A twelfth criterion — whether APC fees are clearly disclosed — is not scored here; it is left out of the total rather than counted as a failure. Publication charges appear in the metrics card above.

Based on the Think.Check.Submit framework by DOAJ, COPE & OASPA. All data from verified open sources.

Source: OpenAlex · Each year’s green bar = citations earned by that year’s papers, counted to date — so recent years look lower simply because their papers haven’t had time to be cited yet.

SJR Quartile by Discipline

Scimago ranks this journal separately in each subject category — its quartile can differ by discipline.

Subject Classification